Page last updated: 2024-10-19

niacinamide and Obesity

niacinamide has been researched along with Obesity in 65 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial."7.96Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020)
"Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive."7.81Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015)
"To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence."7.76Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010)
"NR supplementation of 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism, and induced minor changes in body composition and sleeping metabolic rate."5.34Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. ( Aarts, SABM; Auwerx, J; Connell, NJ; de Wit, VHW; Elfrink, HL; Havekes, B; Hoeks, J; Houtkooper, RH; Lindeboom, L; Lutgens, E; Mevenkamp, J; Moonen, MPB; Phielix, E; Remie, CME; Roumans, KHM; Schomakers, BV; Schrauwen, P; Schrauwen-Hinderling, VB; van de Weijer, T; Zapata-Pérez, R, 2020)
"Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial."3.96Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020)
"Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive."3.81Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015)
"To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence."3.76Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010)
" No serious adverse events due to NR supplementation were observed and safety blood tests were normal."2.87A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. ( Brenner, C; Christensen, B; Dollerup, OL; Jessen, N; Møller, N; Ringgaard, S; Schmidt, MS; Stødkilde-Jørgensen, H; Sulek, K; Svart, M; Treebak, JT, 2018)
"Patients with manifest type 2 diabetes have a significantly (approximately twofold) higher NNMT expression both in omental and subcutaneous WAT compared with controls."2.80Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. ( Blüher, M; Dietrich, A; Kannt, A; Klöting, N; Pfenninger, A; Schön, MR; Teichert, L; Tönjes, A, 2015)
"Obesity is a major health problem, and although caloric restriction and exercise are successful strategies to lose adipose tissue in obese individuals, a simultaneous decrease in skeletal muscle mass, negatively effects metabolism and muscle function."1.48N ( Ahlqvist, E; Almgren, P; Calbet, JAL; de Pablos-Velasco, P; Edlund, A; Ekman, C; Ekström, O; Eliasson, L; Fernandez, C; Groop, L; Hansson, O; Hjort, L; Holmberg, HC; Jörgensen, SW; Martin-Rincon, M; Mattiasson, M; Morales-Alamo, D; Oskolkov, N; Ottosson, F; Pérez-López, A; Perez-Suarez, I; Stenkula, KG; Ström, K; Vaag, A; Wierup, N; Zhou, Y, 2018)
"Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear."1.42Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. ( Côté, CD; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Rutter, GA; Zadeh-Tahmasebi, M, 2015)
" Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight."1.42Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model. ( Funami, H; Igawa, Y; Iwaki, T; Kamiide, Y; Kanki, S; Koyama, M; Maruoka, H; Muto, T; Nagahira, A; Shibata, M; Takahashi, B, 2015)
"In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes."1.40Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. ( Alhonen, L; Asara, JM; Banks, AS; Bhanot, S; Cen, Y; Gong, F; Kahn, BB; Kong, D; Kraus, D; Monia, BP; Peroni, OD; Pirinen, E; Puigserver, P; Pulinilkunnil, TC; Rodgers, JT; Sauve, AA; Wang, YC; Yang, Q; Zhang, L, 2014)
"Obesity is characterized by the accumulation of triacylglycerol in adipocytes."1.37A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. ( Aicher, TD; Kato, K; Kitamura, S; Miki, H; Nakada, Y; Pratt, SA; Yamaguchi, H; Yamamoto, T, 2011)

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19909 (13.85)18.7374
1990's5 (7.69)18.2507
2000's6 (9.23)29.6817
2010's30 (46.15)24.3611
2020's15 (23.08)2.80

Authors

AuthorsStudies
Luo, C1
Yang, C1
Wang, X1
Chen, Y3
Liu, X1
Deng, H1
Ruf, S1
Rajagopal, S1
Kadnur, SV1
Hallur, MS1
Rani, S1
Kristam, R1
Swaminathan, S1
Zope, BR1
Gondrala, PK1
Swamy, I1
Putta, VPRK1
Kandan, S1
Zech, G1
Schreuder, H1
Rudolph, C1
Elvert, R1
Czech, J1
Birudukota, S1
Siddiqui, MA1
Anand, NN1
Mane, VS1
Dittakavi, S1
Suresh, J1
Gosu, R1
Ramesh, M1
Yura, T1
Dhakshinamoorthy, S1
Kannt, A3
Dollerup, OL3
Trammell, SAJ1
Hartmann, B1
Holst, JJ1
Christensen, B2
Møller, N2
Gillum, MP1
Treebak, JT3
Jessen, N3
Shi, W2
Hegeman, MA2
Doncheva, A1
Bekkenkamp-Grovenstein, M1
de Boer, VCJ1
Keijer, J2
Chubanava, S1
Agerholm, M1
Søndergård, SD1
Altıntaş, A1
Møller, AB1
Høyer, KF1
Ringgaard, S2
Stødkilde-Jørgensen, H2
Lavery, GG3
Barrès, R1
Larsen, S1
Prats, C1
Leduc-Gaudet, JP1
Dulac, M1
Reynaud, O1
Ayoub, MB1
Gouspillou, G1
Zhang, J1
Liu, C1
Li, L2
Li, P1
Remie, CME1
Roumans, KHM1
Moonen, MPB1
Connell, NJ1
Havekes, B1
Mevenkamp, J1
Lindeboom, L1
de Wit, VHW1
van de Weijer, T1
Aarts, SABM1
Lutgens, E1
Schomakers, BV1
Elfrink, HL1
Zapata-Pérez, R1
Houtkooper, RH2
Auwerx, J2
Hoeks, J1
Schrauwen-Hinderling, VB1
Phielix, E1
Schrauwen, P1
Fluharty, NT1
Brenner, C3
Moore, MP1
Mucinski, JM1
Yang, X1
Xiong, T1
Ning, D1
Wang, T1
Zhong, H1
Tang, S1
Mao, Y1
Zhu, G1
Wang, D1
Ibrahim, GR1
Shah, I1
Gariballa, S1
Yasin, J1
Barker, J1
Salman Ashraf, S1
de Castro, JM1
Assumpção, JAF1
Stein, DJ1
Toledo, RS1
da Silva, LS1
Caumo, W1
Carraro, CC1
da Rosa Araujo, AS1
Torres, ILS1
Hardy, RS1
Botfield, H1
Markey, K1
Mitchell, JL1
Alimajstorovic, Z1
Westgate, CSJ1
Sagmeister, M1
Fairclough, RJ1
Ottridge, RS1
Yiangou, A1
Storbeck, KH1
Taylor, AE1
Gilligan, LC1
Arlt, W1
Stewart, PM1
Tomlinson, JW1
Mollan, SP1
Sinclair, AJ1
Roberti, A1
Fernández, AF1
Fraga, MF1
Méndez-Lara, KA1
Rodríguez-Millán, E1
Sebastián, D1
Blanco-Soto, R1
Camacho, M1
Nan, MN1
Diarte-Añazco, EMG1
Mato, E1
Lope-Piedrafita, S1
Roglans, N1
Laguna, JC1
Alonso, N1
Mauricio, D1
Zorzano, A1
Villarroya, F1
Villena, JA1
Blanco-Vaca, F1
Julve, J1
Cartwright, DM1
Oakey, LA1
Fletcher, RS1
Doig, CL1
Heising, S1
Larner, DP1
Nasteska, D1
Berry, CE1
Heaselgrave, SR1
Ludwig, C1
Hodson, DJ1
Garten, A1
Ström, K1
Morales-Alamo, D1
Ottosson, F1
Edlund, A1
Hjort, L1
Jörgensen, SW1
Almgren, P1
Zhou, Y3
Martin-Rincon, M1
Ekman, C1
Pérez-López, A1
Ekström, O1
Perez-Suarez, I1
Mattiasson, M1
de Pablos-Velasco, P1
Oskolkov, N1
Ahlqvist, E1
Wierup, N1
Eliasson, L1
Vaag, A1
Groop, L1
Stenkula, KG1
Fernandez, C1
Calbet, JAL1
Holmberg, HC1
Hansson, O1
Kazemi, F1
Zahediasl, S1
Svart, M1
Schmidt, MS1
Sulek, K1
Ying, HZ1
Zang, JN1
Deng, LL1
Wang, ZY1
Yu, CH1
Yang, SJ2
Choi, JM1
Kim, L1
Park, SE1
Rhee, EJ1
Lee, WY1
Oh, KW1
Park, SW1
Park, CY1
Kraus, D1
Yang, Q3
Kong, D1
Banks, AS1
Zhang, L1
Rodgers, JT1
Pirinen, E2
Pulinilkunnil, TC1
Gong, F1
Wang, YC1
Cen, Y2
Sauve, AA2
Asara, JM1
Peroni, OD1
Monia, BP1
Bhanot, S1
Alhonen, L1
Puigserver, P1
Kahn, BB1
Pfenninger, A2
Teichert, L1
Tönjes, A2
Dietrich, A1
Schön, MR1
Klöting, N1
Blüher, M2
Côté, CD2
Rasmussen, BA2
Duca, FA2
Zadeh-Tahmasebi, M2
Baur, JA1
Daljeet, M1
Breen, DM1
Filippi, BM2
Lam, TK2
Rutter, GA1
Koh, EH1
Kim, AR1
Kim, H1
Kim, JH1
Park, HS1
Ko, MS1
Kim, MO1
Kim, HJ1
Kim, BJ1
Yoo, HJ1
Kim, SJ1
Oh, JS1
Woo, CY1
Jang, JE1
Leem, J1
Cho, MH1
Lee, KU1
Lee, HJ1
Hong, YS1
Jun, W1
Takahashi, B2
Funami, H2
Iwaki, T2
Maruoka, H2
Nagahira, A2
Koyama, M2
Kamiide, Y2
Matsuo, T1
Muto, T2
Annoura, H1
Liu, M3
Chu, J2
Zhu, B1
Zhang, Q1
Yin, X1
Jiang, W1
Dai, G1
Ju, W2
Wang, Z2
Fang, Z1
Shibata, M1
Kanki, S1
Igawa, Y1
Zhou, SS3
Li, D3
Fang, ZY1
Trammell, SA1
Weidemann, BJ1
Chadda, A1
Yorek, MS1
Holmes, A1
Coppey, LJ1
Obrosov, A1
Kardon, RH1
Yorek, MA1
Liu, Z1
Gan, L1
Liu, G1
Wu, T1
Feng, F1
Sun, C1
Qi, Z1
Xia, J1
Xue, X1
He, Q1
Ji, L1
Ding, S1
Gu, Y1
Shi, H1
Zhang, R1
Wang, L1
Chen, J1
Shen, L1
Yu, P1
Chen, X1
van Dartel, DAM1
Tang, J1
Suarez, M1
Swarts, H1
van der Hee, B1
Arola, L1
Varela, M1
Reig, M1
de la Mata, M1
Matilla, A1
Bustamante, J1
Pascual, S1
Turnes, J1
Aracil, C1
Del Val, A1
Pascasio, JM1
Rodríguez, M1
Bruix, J1
Sun, WP1
Zhou, YM1
Liu, QG1
Luo, N1
Bian, FN1
Zhao, ZG1
Guo, M1
Yamamoto, T1
Yamaguchi, H1
Miki, H1
Kitamura, S1
Nakada, Y1
Aicher, TD1
Pratt, SA1
Kato, K1
Zhang, LN1
Vincelette, J1
Chen, D1
Gless, RD1
Anandan, SK1
Rubanyi, GM1
Webb, HK1
MacIntyre, DE1
Wang, YX1
Cantó, C1
Youn, DY1
Oosterveer, MH1
Fernandez-Marcos, PJ1
Yamamoto, H1
Andreux, PA1
Cettour-Rose, P1
Gademann, K1
Rinsch, C1
Schoonjans, K1
Pachocka, L1
Kłosiewicz-Latoszek, L1
Broca, C1
Breil, V1
Cruciani-Guglielmacci, C1
Manteghetti, M1
Rouault, C1
Derouet, M1
Rizkalla, S1
Pau, B1
Petit, P1
Ribes, G1
Ktorza, A1
Gross, R1
Reach, G1
Taouis, M1
Larsen, MO2
Juhl, CB1
Pørksen, N2
Gotfredsen, CF2
Carr, RD2
Ribel, U1
Wilken, M2
Rolin, B2
Sturis, J1
Dawson, B1
Favaloro, EJ1
Taylor, J1
Aggarwal, A1
Wu, X1
Wang, M1
Unger, RH2
Zhu, M2
Noma, Y1
Mizuno, A1
Sano, T1
Shima, K2
Shimabukuro, M1
Ohneda, M1
Lee, Y1
Ogino, T1
Murakami, T1
Kuwajima, M1
Piercy, V1
Toseland, CD1
Turner, NC1
Johnson, JT3
Kaplan, ML1
Leveille, GA1
Van Twisk, P1
Braĭko, IV1
Renzetti, AR1
Criscuoli, M1
Subissi, A1
Tochino, Y1
Obrosova, IG1
Kirput', SN1
Ostrovskiĭ, IuM1
Larin, FS1
Efimov, AS1
Mickelsen, O2
Hook, JB2
Gunnarsson, R1
Berne, C1
Hellerström, C1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial[NCT02303483]40 participants (Actual)Interventional2016-01-04Completed
Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans[NCT02835664]15 participants (Actual)Interventional2016-12-31Completed
Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.[NCT02017444]Phase 231 participants (Actual)Interventional2014-04-25Completed
Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors[NCT05684367]24 participants (Anticipated)Interventional2023-11-29Recruiting
NOPARK Open Label Extension Study[NCT05546567]400 participants (Anticipated)Interventional2022-09-28Recruiting
Vitamin B3 as a Novel Mitochondrial Therapy for Obesity[NCT03951285]56 participants (Actual)Interventional2016-05-25Completed
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990]Phase 25 participants (Actual)Interventional2019-11-08Terminated (stopped due to Enrollment challenges)
Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350]54 participants (Anticipated)Interventional2023-11-01Recruiting
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity[NCT02812238]38 participants (Actual)Interventional2016-06-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adverse Events

The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks

InterventionAEs related to intervention (Number)
Placebo0
AZD4017 (11b-HSD1 Inhibitor)9

Anthropometric Measurements (BMI)

The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

Interventionkg/m^2 (Mean)
Placebo37.4
AZD4017 (11b-HSD1 Inhibitor)37.5

Headache-associated Disability

The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache. (NCT02017444)
Timeframe: 12 weeks

InterventionScore on HIT-6 scale (Mean)
Placebo59.8
AZD4017 (11b-HSD1 Inhibitor)60.1

Intracranial Pressure

ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

InterventioncmCSF (Mean)
Placebo-0.3
AZD4017 (11b-HSD1 Inhibitor)-4.3

Serious Adverse Events

The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks

InterventionSerious adverse events (Number)
Placebo1
AZD4017 (11b-HSD1 Inhibitor)0

Diplopia

The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
PresenceAbsence
AZD4017 (11b-HSD1 Inhibitor)215
Placebo111

Headache

The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
PresenceAbsence
AZD4017 (11b-HSD1 Inhibitor)134
Placebo102

Log Contrast Sensitivity

The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionLog contrast senstivity (Mean)
Baseline LCS worst eyeWeek 12 LCS worst eye
AZD4017 (11b-HSD1 Inhibitor)1.631.65
Placebo1.631.66

OCT Total Average Retinal Nerve Fibre Layer Thickness (μm)

The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
Interventionμm (Mean)
Total average retinal nerve fibre layer baseline worst eteTotal average retinal nerve fibre layer week 12 worst eye
AZD4017 (11b-HSD1 Inhibitor)152139.7
Placebo158.4143.2

Papilloedema

"The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.~The modified Frisén scale for grading papilledema using fundus photography is as follows:~Grade 1 - C-Shaped halo with a temporal gap~Grade 2 - The halo becomes circumferential~Grade 3 - Loss of major vessels as they leave the disc~Grade 4 - Loss of major vessels on the disc~Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc~For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711." (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
Frisen grade 0 baselineFrisen grade 0 week 12Frisen grade 1 baselineFrisen grade 1 week 12Frisen grade 2 baselineFrisen grade 2 week 12Frisen grade 3 baselineFrisen grade 3 week 12Frisen grade 4 baselineFrisen grade 4 week 12Frisen grade 5 baselineFrisen grade 5 week 12
AZD4017 (11b-HSD1 Inhibitor)024598002110
Placebo002256331100

Tinnitus

The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
PresenceAbsence
AZD4017 (11b-HSD1 Inhibitor)98
Placebo75

Visual Acuity

The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionLogMAR (log of the minimum angle of reso (Mean)
Baseline LVA worst eyeWeek 12 LVA worst eye
AZD4017 (11b-HSD1 Inhibitor)0.080.06
Placebo0.130.09

Visual Field Mean Deviation

The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionVisual field mean deviation (Mean)
Baseline MD worst eyeWeek 12 MD worst eye
AZD4017 (11b-HSD1 Inhibitor)-6.1-3.4
Placebo-3.4-2.2

Visual Loss

The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
PresenceAbsence
AZD4017 (11b-HSD1 Inhibitor)611
Placebo74

Visual Obscuration

The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
PresenceAbsence
AZD4017 (11b-HSD1 Inhibitor)215
Placebo29

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks

Interventionunits on a scale (Median)
NIAGEN®)7

Difference in Total Neuropathy Score Between Screening and End of Treatment

Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks

Interventionscore on a scale (Median)
NIAGEN®)2

Number of Dose Reduction Events

Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks

Interventionevent (Number)
NIAGEN®)0

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)3

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)0

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks

Interventionng/ml (Median)
NIAGEN®)810

Total Dose of Paclitaxel Administered

Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks

Interventionmg/M^2 (Number)
NIAGEN®)200

Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast

The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. (NCT02812238)
Timeframe: 4 weeks

Interventionmg/dL (Mean)
Nicotinamide Riboside582
Placebo794

Reviews

3 reviews available for niacinamide and Obesity

ArticleYear
Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation.
    Molecular metabolism, 2021, Volume: 45

    Topics: Adipose Tissue; Animals; Epigenesis, Genetic; Humans; Insulin Resistance; Liver; NAD; Neoplasms; Nia

2021
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.
    Diabetes, 1995, Volume: 44, Issue:8

    Topics: Acyl Coenzyme A; Adipocytes; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; F

1995
The NOD mouse as a model of type I diabetes.
    Critical reviews in immunology, 1987, Volume: 8, Issue:1

    Topics: Animals; Autoimmune Diseases; Diabetes Mellitus, Experimental; Female; Gonadal Steroid Hormones; Imm

1987

Trials

6 trials available for niacinamide and Obesity

ArticleYear
Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.
    The Journal of clinical endocrinology and metabolism, 2019, 11-01, Volume: 104, Issue:11

    Topics: Blood Glucose; C-Peptide; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Li

2019
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.
    The Journal of physiology, 2020, Volume: 598, Issue:4

    Topics: Humans; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; NAD; Niacinam

2020
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
    The American journal of clinical nutrition, 2020, 08-01, Volume: 112, Issue:2

    Topics: Acetylcarnitine; Aged; Body Composition; Dietary Supplements; Female; Humans; Male; Middle Aged; Mus

2020
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
    The Journal of clinical endocrinology and metabolism, 2021, 01-01, Volume: 106, Issue:1

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adolescent; Adult; Body Composition; Double-Blind Metho

2021
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
    The American journal of clinical nutrition, 2018, 08-01, Volume: 108, Issue:2

    Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re

2018
Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.
    Diabetologia, 2015, Volume: 58, Issue:4

    Topics: Adult; Aged; Bariatric Surgery; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diabetes

2015

Other Studies

56 other studies available for niacinamide and Obesity

ArticleYear
Nicotinamide reprograms adipose cellular metabolism and increases mitochondrial biogenesis to ameliorate obesity.
    The Journal of nutritional biochemistry, 2022, Volume: 107

    Topics: Adipose Tissue; Animals; Glucose; Mice; NAD; Niacinamide; Nicotinamide Phosphoribosyltransferase; Ob

2022
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.
    Scientific reports, 2022, 09-14, Volume: 12, Issue:1

    Topics: Animals; Glucose; Humans; Metabolic Diseases; Mice; Niacinamide; Nicotinamide N-Methyltransferase; O

2022
High Dose of Dietary Nicotinamide Riboside Induces Glucose Intolerance and White Adipose Tissue Dysfunction in Mice Fed a Mildly Obesogenic Diet.
    Nutrients, 2019, Oct-13, Volume: 11, Issue:10

    Topics: Adipose Tissue, White; Animals; Blood Glucose; Diet, High-Fat; Dose-Response Relationship, Drug; Ene

2019
Nicotinamide riboside supplementation to improve skeletal muscle mitochondrial health and whole-body glucose homeostasis: does it actually work in humans?
    The Journal of physiology, 2020, Volume: 598, Issue:4

    Topics: Dietary Supplements; Glucose; Homeostasis; Humans; Insulin; Male; Muscle, Skeletal; Niacinamide; Obe

2020
N
    Journal of diabetes research, 2020, Volume: 2020

    Topics: Acetylation; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Forkhead Box Protein O1;

2020
Fat mobilization without weight loss is a potentially rapid response to nicotinamide riboside in obese people: it's time to test with exercise.
    The American journal of clinical nutrition, 2020, 08-01, Volume: 112, Issue:2

    Topics: Acetylcarnitine; Body Composition; Dietary Supplements; Humans; Muscle, Skeletal; Niacinamide; Obesi

2020
Impact of nicotinamide riboside supplementation on skeletal muscle mitochondria and whole-body glucose homeostasis: challenging the current hypothesis.
    The Journal of physiology, 2020, Volume: 598, Issue:16

    Topics: Dietary Supplements; Glucose; Homeostasis; Humans; Insulin; Male; Mitochondria, Muscle; Muscle, Skel

2020
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
    Toxicology and applied pharmacology, 2020, 09-01, Volume: 402

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combin

2020
Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.
    Molecules (Basel, Switzerland), 2020, Aug-28, Volume: 25, Issue:17

    Topics: Adolescent; Adult; Biomarkers; Chromatography, Liquid; Cross-Sectional Studies; Female; Humans; Male

2020
Nicotinamide riboside reduces cardiometabolic risk factors and modulates cardiac oxidative stress in obese Wistar rats under caloric restriction.
    Life sciences, 2020, Dec-15, Volume: 263

    Topics: Animals; Antioxidants; Caloric Restriction; Cardiometabolic Risk Factors; Insulin Resistance; Male;

2020
Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging.
    Molecular nutrition & food research, 2021, Volume: 65, Issue:11

    Topics: Adipocytes, Beige; Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anim

2021
Nicotinamide riboside has minimal impact on energy metabolism in mouse models of mild obesity.
    The Journal of endocrinology, 2021, 09-09, Volume: 251, Issue:1

    Topics: Animals; Cell Respiration; Diet, High-Fat; Disease Models, Animal; Drug Evaluation; Energy Metabolis

2021
N
    Scientific reports, 2018, 02-14, Volume: 8, Issue:1

    Topics: Adult; Body Mass Index; Caloric Restriction; Cells, Cultured; Energy Metabolism; Exercise; Exercise

2018
Effects of exercise training on adipose tissue apelin expression in streptozotocin-nicotinamide induced diabetic rats.
    Gene, 2018, Jul-01, Volume: 662

    Topics: Adipose Tissue; Animals; Apelin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabet

2018
Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 62

    Topics: Adipogenesis; Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Gene Expression Regula

2013
Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.
    The Journal of nutritional biochemistry, 2014, Volume: 25, Issue:1

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models,

2014
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
    Nature, 2014, Apr-10, Volume: 508, Issue:7495

    Topics: Acetyltransferases; Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Diabetes Mellitus, T

2014
Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.
    Nature medicine, 2015, Volume: 21, Issue:5

    Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Gene Expression Reg

2015
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
    Nature medicine, 2015, Volume: 21, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Gene Exp

2015
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
    The Journal of endocrinology, 2015, Volume: 225, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue,

2015
Nicotinamide Riboside Ameliorates Hepatic Metaflammation by Modulating NLRP3 Inflammasome in a Rodent Model of Type 2 Diabetes.
    Journal of medicinal food, 2015, Volume: 18, Issue:11

    Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Apoptosis Regulatory Proteins; Blood Glucose; CARD S

2015
2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
    Bioorganic & medicinal chemistry letters, 2015, Jul-01, Volume: 25, Issue:13

    Topics: Animals; Anti-Obesity Agents; Appetite Regulation; Drug Design; HEK293 Cells; High-Throughput Screen

2015
Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:8

    Topics: Adult; Asian People; Body Mass Index; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem

2015
Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
    Bioorganic & medicinal chemistry, 2015, Aug-01, Volume: 23, Issue:15

    Topics: Administration, Oral; Animals; Anti-Obesity Agents; Disease Models, Animal; Drug Inverse Agonism; Ha

2015
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].
    Diabetologia, 2015, Volume: 58, Issue:9

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met

2015
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake?
    Diabetologia, 2015, Volume: 58, Issue:9

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met

2015
Letter to the Editor: High Serum N(1)-Methylnicotinamide in Obesity and Diabetes: A Consequence of Excess Nicotinamide?
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:9

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Niacinamide; Obesity

2015
Response to the Letter by Zhou, et al.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:9

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Niacinamide; Obesity

2015
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
    Scientific reports, 2016, 05-27, Volume: 6

    Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F

2016
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
    Scientific reports, 2016, 05-27, Volume: 6

    Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F

2016
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
    Scientific reports, 2016, 05-27, Volume: 6

    Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F

2016
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
    Scientific reports, 2016, 05-27, Volume: 6

    Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F

2016
Sirt1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice.
    Journal of lipid research, 2016, Volume: 57, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Animals; Anti-Obesity Agents; Cells, Cultured; Diet, High-Fat;

2016
Long-term treatment with nicotinamide induces glucose intolerance and skeletal muscle lipotoxicity in normal chow-fed mice: compared to diet-induced obesity.
    The Journal of nutritional biochemistry, 2016, Volume: 36

    Topics: Animals; Antioxidants; Autophagy; Diet, High-Fat; Dietary Supplements; Gene Expression Regulation; G

2016
Serum N1-Methylnicotinamide is Associated With Coronary Artery Disease in Chinese Patients.
    Journal of the American Heart Association, 2017, 02-07, Volume: 6, Issue:2

    Topics: Aged; Biomarkers; Body Mass Index; China; Chromatography, Liquid; Comorbidity; Coronary Angiography;

2017
Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet.
    Molecular nutrition & food research, 2017, Volume: 61, Issue:8

    Topics: Adipokines; Adipose Tissue, White; Animals; Blood Glucose; Carbohydrate Metabolism; Diet; Dietary Su

2017
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
    Medicina clinica, 2010, May-08, Volume: 134, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;

2010
Chronic niacin overload may be involved in the increased prevalence of obesity in US children.
    World journal of gastroenterology, 2010, May-21, Volume: 16, Issue:19

    Topics: Adolescent; Adult; Appetite; Biomarkers; Blood Glucose; Child; Child, Preschool; Feeding Behavior; G

2010
A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
    European journal of pharmacology, 2011, Jan-15, Volume: 650, Issue:2-3

    Topics: Adipose Tissue; Animals; Body Weight; Diacylglycerol O-Acyltransferase; Dietary Carbohydrates; Dieta

2011
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
    European journal of pharmacology, 2011, Mar-01, Volume: 654, Issue:1

    Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus

2011
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
[Changes in vitamins intake in overweight and obese adults after low-energy diets].
    Roczniki Panstwowego Zakladu Higieny, 2002, Volume: 53, Issue:3

    Topics: Adult; Ascorbic Acid; Avitaminosis; Diet Records; Diet Surveys; Diet, Fat-Restricted; Female; Humans

2002
Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.
    American journal of physiology. Endocrinology and metabolism, 2004, Volume: 287, Issue:3

    Topics: Animals; Diabetes Mellitus, Experimental; Diet; Enzyme Activation; Glucose; Glucose Clamp Technique;

2004
Beta-cell function and islet morphology in normal, obese, and obese beta-cell mass-reduced Göttingen minipigs.
    American journal of physiology. Endocrinology and metabolism, 2005, Volume: 288, Issue:2

    Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Dietary Fats; Insulin; Ins

2005
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Göttingen minipigs in vivo.
    American journal of physiology. Endocrinology and metabolism, 2006, Volume: 290, Issue:4

    Topics: Animals; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucose Tolerance Te

2006
Unrecognized pellagra masquerading as odynophagia.
    Internal medicine journal, 2006, Volume: 36, Issue:7

    Topics: Aged; Deglutition Disorders; Diagnostic Errors; Female; Humans; Niacinamide; Obesity; Pellagra; Prea

2006
Dietary nicotinamide supplementation increases xanthine oxidoreductase activity in the kidney and heart but not liver of obese Zucker rats.
    The Journal of nutrition, 1995, Volume: 125, Issue:7

    Topics: Animals; Female; Food, Fortified; Heart; Kidney; Liver; Myocardium; Niacinamide; Obesity; Organ Size

1995
Poor capacity for proliferation of pancreatic beta-cells in Otsuka-Long-Evans-Tokushima Fatty rat: a model of spontaneous NIDDM.
    Diabetes, 1996, Volume: 45, Issue:7

    Topics: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe

1996
Role of nitric oxide in obesity-induced beta cell disease.
    The Journal of clinical investigation, 1997, Jul-15, Volume: 100, Issue:2

    Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids,

1997
Effect of partial pancreatectomy on beta-cell mass in the remnant pancreas of Wistar fatty rats.
    The journal of medical investigation : JMI, 1998, Volume: 45, Issue:1-4

    Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models,

1998
Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:12

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycosuria; Hyperglycemia; Insulin;

2000
Renal transport of organic acids and bases in genetically obese mice.
    Canadian journal of physiology and pharmacology, 1975, Volume: 53, Issue:3

    Topics: Acetates; Aminohippuric Acids; Animals; Body Weight; Disease Models, Animal; Female; Hyperglycemia;

1975
The role of technology in modern nutrition.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1976, May-01, Volume: 50, Issue:19

    Topics: Adult; Child; Food Preservation; Food Supply; Food Technology; Food, Formulated; Food, Fortified; Hu

1976
[Use of phenatine in complex sanatorium-health resort treatment of hypertensive disease with obesity nutritional].
    Vrachebnoe delo, 1975, Issue:10

    Topics: Adult; Appetite Depressants; Health Resorts; Humans; Hypertension; Male; Middle Aged; Niacinamide; O

1975
Further assessment of glunicate hypolipidaemic activity in the rat.
    The Journal of pharmacy and pharmacology, 1985, Volume: 37, Issue:12

    Topics: Animals; Blood Glucose; Female; Hypolipidemic Agents; Lipids; Male; Niacin; Niacinamide; Obesity; Ra

1985
[The action of nicotinamide on the adenine nucleotide system as well as on mitochondrial oxidation and phosphorylation processes in the liver of db/db strain mice].
    Biulleten' eksperimental'noi biologii i meditsiny, 1988, Volume: 106, Issue:12

    Topics: Adenine Nucleotides; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Mice; Mice, Inbred C57BL

1988
Effect of obesity in the rat on renal transport of organic acids and bases.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1973, Volume: 142, Issue:1

    Topics: Age Factors; Aminohippuric Acids; Animals; Biological Transport; Body Weight; Carbon Isotopes; Dieta

1973
Factors contributing to depressed renal transport of organic anions in the obese rat.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1973, Volume: 143, Issue:4

    Topics: Age Factors; Aminohippuric Acids; Animals; Biological Transport; Dietary Fats; In Vitro Techniques;

1973
Cytotoxic effects of streptozotocin and N-nitrosomethylurea on the pancreatic B cells with special regard to the role of nicotinamide-adenine dinucleotide.
    The Biochemical journal, 1974, Volume: 140, Issue:3

    Topics: Adenosine Triphosphate; Animals; Blood Glucose; Female; Glucose; Hyperglycemia; Insulin; Insulin Sec

1974